drugset
drugset / Trial / NCT00530621

Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer

NCT00530621 ↗

Phase 2 Completed 160 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if the combination of enzastaurin and pemetrexed can extend survival time without progression of disease for participants who have advanced or metastatic non-small cell lung cancer (NSCLC).

Timeline

Start
2007-09
Primary completion
2008-10
Completion
2008-10

Outcome

Missed primary endpoint

registry Pemetrexed + Enzastaurin vs Pemetrexed + Placebo; p = 0.544; Hazard Ratio (HR) 1.13 (95% CI 0.77 to 1.65) NCT00530621 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject enzastaurin Small molecule 500 mg Oral
Background Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma